EP3920721A1 - Composition antioxydante comprenant de la quercétagétine et de l'acide gallique - Google Patents

Composition antioxydante comprenant de la quercétagétine et de l'acide gallique

Info

Publication number
EP3920721A1
EP3920721A1 EP20703041.2A EP20703041A EP3920721A1 EP 3920721 A1 EP3920721 A1 EP 3920721A1 EP 20703041 A EP20703041 A EP 20703041A EP 3920721 A1 EP3920721 A1 EP 3920721A1
Authority
EP
European Patent Office
Prior art keywords
combination
gallic acid
extract
quercetagetin
antioxidant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20703041.2A
Other languages
German (de)
English (en)
Inventor
Javier ESTÉVEZ MEDINA
Miquel PARAIRA BESER
Sergi CARNÉ FRUCTUOSO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INDUSTRIAL TECNICA PECUARIA SA
Original Assignee
INDUSTRIAL TECNICA PECUARIA SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INDUSTRIAL TECNICA PECUARIA SA filed Critical INDUSTRIAL TECNICA PECUARIA SA
Publication of EP3920721A1 publication Critical patent/EP3920721A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
    • A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
    • A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
    • A23L3/3463—Organic compounds; Microorganisms; Enzymes
    • A23L3/3472—Compounds of undetermined constitution obtained from animals or plants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
    • A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
    • A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
    • A23L3/3463—Organic compounds; Microorganisms; Enzymes
    • A23L3/3481—Organic compounds containing oxygen
    • A23L3/3508—Organic compounds containing oxygen containing carboxyl groups
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
    • A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
    • A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
    • A23L3/3463—Organic compounds; Microorganisms; Enzymes
    • A23L3/3544—Organic compounds containing hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives

Definitions

  • Antioxidant composition comprising quercetagetin and gallic acid
  • the present invention belongs to the field of antioxidants.
  • antioxidants for preserving foods, feeds, pharmaceutical or cosmetic compositions are particularly useful for preserving lipid-containing compositions.
  • oxidation is highly relevant. It particularly affects fats, leading to lipid oxidation.
  • lipid oxidation is a major cause of stored products spoilage, causing flavor deterioration, color alteration and bad odors.
  • Polyunsaturated fatty acids (PUFA) with labile double bonds are oxidized and the decomposition of PUFA produces secondary oxidative compounds, such as hexanal, pentanal, heptanal, and octanal. These volatile aldehydes mostly contribute to the development of oxidative rancidity known as warmed-over flavor (WOF).
  • Secondary oxidative compounds are not only responsible for quality deterioration of food, but ingested oxidative products can also be a risk for human and animal health.
  • lipid- containing products such as food for human consumption, animal feed, pharmaceuticals or even cosmetic products.
  • antioxidant compounds have been preferably employed because of their potential health benefits and safety. Some examples are tocopherols and phospholipids such as lecithin. Likewise, many natural plant extracts are under strong investigation because of their high antioxidant content, including flavonoids and other polyphenols.
  • antioxidants used so far present various disadvantages, for instance, tocopherol based antioxidants are expensive and their efficacy vary as a preservative.
  • the inventors have developed a new combination of compounds for improving the oxidative stability of various types of compositions.
  • the combination of the invention comprises a mixture of quercetagetin and gallic acid at specific ratios.
  • the invention provides a combination comprising quercetagetin and gallic acid at a weight ratio from 65: 1 to 1.2: 1 , wherein the gallic acid is in acid form, or in the form of a salt or an ester thereof.
  • the invention provides a food, animal feed, pharmaceutical, veterinarian, or cosmetic composition comprising the combination as defined above.
  • the invention provides the use of the combination as defined above as an antioxidant in a food, animal feed, pharmaceutical, veterinarian, or cosmetic composition.
  • the invention provides a method for preparing the combination as defined above, comprising the steps of providing quercetagetin; adding gallic acid;
  • Fig. 1 shows the antioxidant efficacy of a Tagetes erecta extract (quercetagetin), gallic acid and combinations thereof at the concentrations indicated.
  • the y-axis represents the protection factor (PF) (calculated as explained in the examples below), and the x-axis represents the concentration of active substances (antioxidants) tested.
  • the values obtained with gallic acid are represented by empty squares, TE extract by empty circles, a mixture of TE extract and gallic acid at a weight ratio 15:1 by black triangles, at a weight ratio 5:1 by black circles, at a weight ratio 1.67:1 by empty triangles, and at a weight ratio 1 :1.8 by black triangles.
  • N 4-8 replicates per concentration of antioxidants tested.
  • Two- way Anova (Test Tukey), * P ⁇ 0.05 vs. TE, # P ⁇ 0.01 vs. gallic acid.
  • Fig. 2 shows the antioxidant efficacy of quercetagetin, Tagetes erecta extract, gallic acid and combinations thereof at the concentrations indicated.
  • the y-axis represents the protection factor (PF) (calculated as explained in the examples below), and the x-axis represents the concentration of active substances (antioxidants) tested.
  • PF protection factor
  • the values obtained with gallic acid are represented by empty circles, quercetagetin by empty squares, TE extract by empty triangles, a mixture of TE extract and gallic acid at a weight ratio 15:1 by black triangles pointing down, a mixture of TE extract and gallic acid at a weight ratio 5:1 by black triangles pointing up, and a mixture of quercetagetin and gallic acid at a weight ratio 9:1 by black circles.
  • N 4-14 replicates per concentration of antioxidants tested. Two-way Anova (Test Tukey), different letters in each assessed concentration represents significant differences (P ⁇ 0.05).
  • the present invention provides a combination of quercetagetin, and gallic acid at a weight ratio from 65: 1 to 1.2: 1 , wherein when the gallic acid is in acid form or in the form of a salt or an ester thereof. Where the gallic acid is in the form of a salt or ester thereof, the weight ratio relates to the corresponding amount of gallic acid.
  • weight ratio refers to the relation of weights of the molecules or compounds indicated. For instance, a weight ratio (weight/weight) of 65:1 between quercetagetin and gallic acid refers to 65 units of quercetagetin and 1 unit of gallic acid.
  • % by weight or“% w/w” of a component refers to the amount of the single component relative to the total weight of the composition or, if specifically mentioned, of other component.
  • the weight of an extract refers to the dry extract weight or mass.
  • Quercetagetin is also known as 2-(3,4-dihydroxyphenyl)-3,5,6,7-tetrahydroxychromen-4- one, and has a CAS number 90-18-6. Quercetagetin has the formula (I):
  • Gallic acid is also known as 3,4,5-trihydroxybenzoic acid, and has a CAS number 149-91- 7.
  • Gallic acid has the formula (II):
  • gallates Several salts and esters of gallic acid, which are called gallates, are known to also have antioxidant activity and, thus, can be used in the combinations of the invention.
  • alkyl esters of gallic acid such as methyl gallate, propyl gallate, octyl gallate, and dodecyl (lauryl) gallate, or gallic acid salts such as sodium gallate, can be combined with quercetagetin to obtain a synergic antioxidant combination.
  • Quercetagetin and gallic acid are commercially available and can be obtained from several chemical suppliers.
  • the gallic acid ester is an alkyl ester, such as a C1-C12 alkyl ester.
  • the gallic acid ester is selected from the group consisting of methyl gallate, ethyl gallate, propyl gallate, octyl gallate, dodecyl gallate, and mixtures thereof.
  • the preparation of the gallic acid salts can be carried out by methods known in the art.
  • gallic acid esters can be prepared by methods known in the art. In general, gallic acid esters are prepared, for example, by reacting the free acid form of the gallic acid with a stoichiometric amount of the appropriate alcohol at high temperatures. In another embodiment of the combination of the invention, optionally in combination with any of the embodiments provided above or below, the gallic acid is in acid form.
  • the weight ratio between quercetagetin and gallic acid or the salt or ester thereof is from 65:1 to 1.2:1, from 64:1 to 1.2:1, from 63:1 to 1.2:1, from 62:1 to 1.2:1, from 61.2:1 to 1.2:1, from 60:1 to 1.2:1, from 59:1 to 1.2:1, from 58:1 to 1.2:1, from 57:1 to 1.2:1, from 56:1 to 1.2:1, from 55:1 to 1.2:1, from 54:1 to 1.2:1, from 53:1 to 1.2:1, from 52:1 to 1.2:1, from 51.2:1 to 1.2:1, from 50:1 to 1.2:1, from 49:1 to 1.2:1, from 48:1 to 1.2:1, from 47:1 to 1.2:1, from 46:1 to 1.2:1, from 45:1 to 1.2:1, from 44:1 to 1.2:1, from 43:
  • the weight ratio between quercetagetin and gallic acid or the salt or ester thereof is from 10:1 to 1.2:1, from 10:1 to 1.3:1, from 10:1 to 1.4:1, from 10:1 to 1.5:1, from 10:1 to 1.6:1, from 10:1 to 1.7:1, from 10:1 to 1.8:1, from 10:1 to 1.9:1, from 10:1 to 2:1, from 10:1 to 2.1:1, from 10:1 to 2.2:1, from 10:1 to 2.3:1, from 10:1 to 2.4:1, from 10:1 to 2.5:1, from 10:1 to 2.6:1, from 10:1 to 2.7:1, from 10:1 to 2.8:1, or from 10:1 to 2.9:1.
  • the combination consists of
  • quercetagetin and gallic acid at a weight ratio from 65:1 to 1.2:1.
  • the combination comprises
  • the combination comprises quercetagetin and gallic acid at a weight ratio from 65:1 to 1.2:1, more particularly from 20:1 to 1.5:1, more particularly, from 10:1 to 1.5:1, more particularly, from 10:1 to 2:1, more particularly, from 4:1 to 2:1, or even more particularly, from 8.6:1 to 2.85:1. More particularly, the combination comprises quercetagetin and gallic acid at a weight ratio from 49:1 to 1.5:1. More particularly, the combination comprises quercetagetin and gallic acid at a weight ratio from 9: 1 to 1.5: 1.
  • the quercetagetin is provided in the form of a plant extract.
  • plant extract or“extract” refers to concentrated preparations of various parts of plants obtained by isolating the active constituents, such as antioxidants, from the plant by suitable means.
  • suitable means for their isolation can be used, for example, aqueous solutions, alcoholic solutions, organic solvents, microwave or supercritical fluids extraction.
  • Said extracts contain one or more active ingredients and may be incorporated in compositions in a variety of forms, including a pure or semi-pure component, a solid or liquid extract, or a solid plant matter.
  • the plant extract comprises quercetagetin in an amount equal to or higher than 30 %w/w of dry extract mass, more in particular, equal to or higher than 40 %w/w of dry extract mass, even more in particular, equal to or higher than 50 %w/w of dry extract mass, and even more in particular, from 35 to 60 %w/w of dry extract mass.
  • the plant extract is a Tagetes erecta extract.
  • the Tagetes erecta extract is a flower bagasse extract.
  • the Tagetes erecta flower bagasse extract comprises quercetagetin in an amount from 35 to 60 %w/w of dry extract mass.
  • Tagetes erecta extract it is understood a concentrated preparation of compounds obtained from the Tagetes erecta plant.
  • the flower bagasse is the remaining residue after extracting the oleoresin from the flowers.
  • the main antioxidant compound of the Tagetes erecta flower bagasse extract is quercetagetin, which accounts for more than 94% of its antioxidant (see the examples below).
  • Tagetes erecta also known as Mexican marigold, Aztec marigold, African marigold, or simply, marigold
  • Tagetes erecta is an herbaceous plant belonging to the family Asteraceae. This plant has been usually used in traditional medicine and is a common ornamental plant around the world.
  • Marigold oleoresins are used by the industry as a source of natural carotenoids to produce, for instance, pigments to be added in feed for broiler chicken or laying hens.
  • Carotenoid-rich oleoresin is obtained from dried marigold flowers with hexane, generating high amounts of defatted flower residues or bagasse. These residues are currently used as a fiber source for animals, as fertilizer or simply discarded.
  • an additional advantage of the combinations of the invention is that quercetagetin can be obtained from abundant and inexpensive compounds that are commonly discarded in industry, such as the Tagetes erecta bagasse extract, which is highly enriched in quercetagetin.
  • the plant extract is selected from the group consisting of an aqueous extract, an alcoholic extract, and an organic extract.
  • the plant extract is an alcoholic extract.
  • aqueous extract refers to a plant extract where the extraction has been performed using water as the only solvent.
  • organic extract refers to a plant extract where the extraction has been performed using an organic solvent that is not an alcohol.
  • alcoholic extract refers to a plant extract where the extraction has been performed using a mixture of water and an alcohol, such as methanol or ethanol.
  • the extract is a dry extract.
  • the weight ratio of the extract and gallic acid should be adjusted depending on the amount of quercetagetin contained in the extract to obtain the ratios of the present invention. For example, as shown in the examples below, where a Tagetes erecta extract containing quercetagetin at 57 % w/w is used, a combination of the extract and gallic acid at a weight ratio of 5:1 has to be made in order to obtain a 2.85:1 weight ratio of quercetagetin and gallic acid.
  • the combination comprises a Tagetes erecta extract and gallic acid in a weight ratio from 65:1 to 1.8:1 , more in particular from 18:1 to 3:1 , even more in particular from 16:1 to 4:1 , and even more in particular, from 15:1 to 5:1.
  • a Tagetes erecta extract and gallic acid in a weight ratio from 65:1 to 1.8:1 , more in particular from 18:1 to 3:1 , even more in particular from 16:1 to 4:1 , and even more in particular, from 15:1 to 5:1.
  • the combination comprises a Tagetes erecta extract and added gallic acid in a weight ratio from 90:1 to 1.8:1 , more in particular from 40: 1 to 3: 1 , even more in particular from 20: 1 to 4: 1 , and even more in particular, from 15:1 to 5:1.
  • the combination comprises a Tagetes erecta alcoholic extract and added gallic acid in a weight ratio from 90:1 to 1.8:1 , more in particular from 40: 1 to 3: 1 , even more in particular from 20: 1 to 4: 1 , and even more in particular, from 15:1 to 5:1.
  • the combination comprises a Tagetes erecta flower bagasse alcoholic extract and added gallic acid in a weight ratio from 90:1 to 1.8:1 , more in particular from 40:1 to 3:1 , even more in particular from 20:1 to 4:1 , and even more in particular, from 15:1 to 5:1.
  • the invention provides in a second embodiment a food, animal feed, pharmaceutical, veterinarian, or cosmetic composition comprising the combination as defined above.
  • the compositions of the invention can additionally incorporate other active ingredients which reinforce the beneficial effects of the combination of the invention.
  • A“food composition”, as used herein, refers to any solid, semi-solid, or liquid composition, also a drinkable liquid, which is suitable for human consumption.
  • the term“animal feed composition” refers to any solid, semi-solid, or liquid composition, also a drinkable liquid, which is suitable for non-human animal consumption; therefore, it also encompasses pet food. Both food and feed compositions are meant to also encompass the raw materials and feedstock used for their elaboration, as well as dietary supplements.
  • the term“dietary supplement” refers to a preparation intended to supplement the diet and provide nutrients, such as vitamins, minerals, fiber, fatty acids, or amino acids, that may be missing or may not be consumed in sufficient quantity in a subject’s diet.
  • Cosmetic composition refers to compositions for improving the appearance or hygiene of subjects, comprising cosmetically acceptable excipients or carriers.
  • cosmetically acceptable refers to that excipients or carriers suitable for use in contact with human skin without undue toxicity, incompatibility, instability, allergic response, among others.
  • pharmaceutical composition or“veterinarian composition” refer to compositions used for improving or maintaining the health of subjects or animals, respectively, and comprise pharmaceutically acceptable excipients or carriers.
  • compositions comprising the combination of the invention can be presented in any form, for example, solid or liquid.
  • the combination of the invention is particularly useful to prevent the oxidation of composition comprising lipids.
  • the food, animal feed optionally in combination with any of the embodiments provided above or below, the food, animal feed,
  • composition comprises lipids. More particularly, the composition comprises an amount of lipids equal to or higher than 1 % w/w, even more particular equal to or higher than 10 % w/w.
  • lipids refers to organic molecules that are insoluble in water and soluble in nonpolar solvents, for example, fatty acids, steroids, or triacylglycerides (fats).
  • the combination of the invention is especially useful for preventing the oxidation of fats.
  • the food, animal feed, pharmaceutical, veterinarian, or cosmetic composition comprises vitamins or carotenoids.
  • the food, animal feed, pharmaceutical, veterinarian, or cosmetic composition comprises the combination of the invention in an amount from 0.001 % w/w to 1 % w/w, more in particular from 0.005% w/w to 0.5% w/w, and even more in particular, from 0.01 % w/w to 0.1 % w/w.
  • the food, animal feed, pharmaceutical, veterinarian, or cosmetic composition comprises quercetagetin in an amount from 20 ppm to 5000 ppm. More particularly, from 25 ppm to 500 ppm, and even more particularly, from 50 ppm to 200 ppm.
  • the food, animal feed, pharmaceutical, veterinarian, or cosmetic composition comprises gallic acid in an amount from 20 ppm to 5000 ppm. More particularly, from 25 ppm to 500 ppm, and even more particularly, from 50 ppm to 200 ppm.
  • the invention provides in a third aspect the use of the combination as defined above as an antioxidant in a food, animal feed, pharmaceutical, veterinarian, or cosmetic composition.
  • the combination of the invention is useful for increasing the oxidative stability of any composition that comprises oxidation-sensitive molecules, for instance lipids.
  • the combination as defined above is used as an antioxidant in a food, animal feed, pharmaceutical, veterinarian, or cosmetic composition, wherein the compositions comprises lipids, more particularly, it comprises an amount of lipids equal to or higher than 1 % w/w, even more particular equal to or higher than 10 % w/w.
  • the invention provides in a fourth aspect a method for preparing the combination as defined above, comprising the steps of:
  • the suitable liquid carrier is selected from the group consisting of an edible carrier and a pharmaceutically acceptable carrier.
  • the suitable liquid carrier is selected from group consisting of alcohol (such as ethanol or isopropanol), organic acid, ester (such as citrates,
  • A“pharmaceutical acceptable carrier” as used herein, refers to a carrier suitable for use in contact with the tissue or organ of humans and non-human animals without excessive toxicity, irritation, allergic response, immunogenicity or other problems or complications commensurate with a reasonable benefit/risk ratio.
  • An“edible carrier” refers to a carrier that can be ingested by animals, including humans, without significant deleterious health consequences.
  • the bagasse of Tagetes erecta was obtained by subjecting the flowers to oleoresin extraction (H. B. Sowbhagya et at.,“Natural Colorant from Marigold-Chemistry and Technology”, Food Reviews International, 2004, vol. 20, pp. 33-50).
  • the bagasse was subjected to alcoholic solvent extraction according to standard procedures.
  • the extraction may be carried out using as solvent methanol and/or ethanol in water at volume ratios ranging from 1 :3 to 3:1 , a range of temperatures from 30 to 50 °C during periods of time from 0.5 to 2 hours, and with a solid-to-liquid ratio from 1 :30 to 1 :50 (w/v), depending on the characteristics of the raw materials.
  • the solid-liquid intermediate product was later filtered and the extract was spray dried to obtain a concentrated yellow to brown powder.
  • the set of operating conditions for concentration-filtration and spray drying of the extract are dependent on the specific characteristics of each batch of extract, which is influenced by quality of the original crop where obtained. Ingredients added to the preparation to be spray dried also determine operating conditions as well.
  • the solid residue and viscosity is standardized among extract batches. A two-fluid nozzle with a cap-orifice diameter of 0.5 mm was used.
  • the aqueous dispersion is mixed for approximately 30 min before spray-drying within this reference range of operating conditions: drying air inlet temperature, 100-170°C;
  • atomization air volumetric flowrate 300-800 l/h; feed volumetric flowrate: 3-15 ml/min; feed concentration, 3-10% (w/w); drying air volumetric flowrate: 25-50 m 3 /h.
  • quercetagetin represents practically all the antioxidant substances of the extract (94.24 % of the assessed active substances in these samples). Quercetin represents a 4.39% of the assessed phenolics and flavonoids assessed and gallates including methyl-gallate and gallic acid represent a 1.37% (1.17% and 0.20%,
  • Rancimat assays were performed with 892 Professional Rancimat according to manufacturer’s instructions (Metrohm, Switzerland), in order to assess the antioxidant efficacy of quercetagetin (provided in the form of a Tagetes erecta bagasse extract above described) in combination with various antioxidants.
  • the temperature of the heating block was fixed at 120 °C.
  • 60 ml_ of deionized water was added to each cell and its conductivity was determined until it was stable (1.5 - 2 h).
  • the antioxidant protection factors were determined by the ratio of the induction period with antioxidant to the induction period of the respective negative control (without antioxidant). The higher the antioxidant protection factor, the better the efficacy of the antioxidant assessed. SAS Software version 9.1.3 (SAS institute) was used to perform all statistical analysis. Results with TE extract combined with gallic acid
  • n 2 (replicates per each concentration)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La présente invention concerne une combinaison comprenant de la quercétagétine et de l'acide gallique selon un rapport de poids de 65:1 à 1,2:1, l'acide gallique étant sous forme acide, ou sous la forme d'un sel ou d'un ester de celui-ci. La présente invention concerne également un aliment, de la nourriture pour animaux, une composition pharmaceutique ou cosmétique comprenant la combinaison de l'invention. La présente invention concerne également l'utilisation de la combinaison selon l'invention en tant qu'antioxydant dans un aliment, de la nourriture pour animaux, une composition pharmaceutique, vétérinaire ou cosmétique. La combinaison selon l'invention est très utile pour empêcher l'oxydation de compositions comprenant des lipides.
EP20703041.2A 2019-02-08 2020-02-07 Composition antioxydante comprenant de la quercétagétine et de l'acide gallique Pending EP3920721A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19382089 2019-02-08
EP19382114 2019-02-19
PCT/EP2020/053157 WO2020161312A1 (fr) 2019-02-08 2020-02-07 Composition antioxydante comprenant de la quercétagétine et de l'acide gallique

Publications (1)

Publication Number Publication Date
EP3920721A1 true EP3920721A1 (fr) 2021-12-15

Family

ID=69411465

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20703041.2A Pending EP3920721A1 (fr) 2019-02-08 2020-02-07 Composition antioxydante comprenant de la quercétagétine et de l'acide gallique

Country Status (5)

Country Link
EP (1) EP3920721A1 (fr)
CN (1) CN113613508A (fr)
BR (1) BR112021014774A2 (fr)
MX (1) MX2021009392A (fr)
WO (1) WO2020161312A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113621440A (zh) * 2020-05-06 2021-11-09 晨光生物科技集团股份有限公司 一种具有较好稳定性的油脂组合物
CN113615767B (zh) * 2020-05-06 2023-05-05 晨光生物科技集团股份有限公司 一种包含槲皮万寿菊素的饲料及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010047032A1 (en) * 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
ITRM20010600A1 (it) * 2001-10-04 2003-04-04 Brane Tech S R L Composti flavonoidici capaci di modificare lo stato fisico e/o dinamico di membrane biologiche e di stimolare la sintesi endogena di protein
AU2003263162B2 (en) * 2002-10-24 2009-05-07 Immupharm A/S Pharmaceutical compositions comprising flavonoids and menthol
BRPI0704096E2 (pt) * 2006-12-27 2009-09-15 Kraft Foods Holdings Inc método para reduzir significantemente os nìveis de adstringência e amargor em composições de polifenol, e, composição

Also Published As

Publication number Publication date
CN113613508A (zh) 2021-11-05
MX2021009392A (es) 2021-11-12
WO2020161312A1 (fr) 2020-08-13
BR112021014774A2 (pt) 2021-09-28

Similar Documents

Publication Publication Date Title
Wang et al. Effects of a natural antioxidant, polyphenol-rich rosemary (Rosmarinus officinalis L.) extract, on lipid stability of plant-derived omega-3 fatty-acid rich oil
US5527552A (en) Lipid-soluble green tea catechin antioxidant solutions
Benakmoum et al. Valorisation of low quality edible oil with tomato peel waste
Gharibzahedi et al. Evaluation of physicochemical properties and antioxidant activities of Persian walnut oil obtained by several extraction methods
Djenontin et al. Composition of Azadirachta indica and Carapa procera (Meliaceae) seed oils and cakes obtained after oil extraction
Marmouzi et al. Proximate analysis, fatty acids and mineral composition of processed Moroccan Chenopodium quinoa Willd. and antioxidant properties according to the polarity
CA2734477C (fr) Composition antioxydante pour huiles marines renfermant du tocopherol, de l'extrait de romarin, de l'acide ascorbique et de l'extrait de the vert, ledit extrait de the vert renfermant un porteur polysaccharide
Fernandes et al. Natural antioxidants and food applications: healthy perspectives
Faria et al. Antioxidant efficacy and in silico toxicity prediction of free and spray-dried extracts of green Arabica and Robusta coffee fruits and their application in edible oil
WO2020161312A1 (fr) Composition antioxydante comprenant de la quercétagétine et de l'acide gallique
US20120219647A1 (en) Antioxidant composition
Xia et al. Functional and emulsification characteristics of phospholipids and derived o/w emulsions from peony seed meal
US9579301B2 (en) Organic emulsion comprising DHA and EPA
Chirinos et al. Antioxidants from Mashua (T ropaeolum tuberosum) Control Lipid Oxidation in Sacha Inchi (P lukenetia volubilis L.) Oil and Raw Ground Pork Meat
Shi et al. Antioxidants extraction by supercritical CO2
EP2285242B1 (fr) Combinaisons d'extrait vegetal et d'acides gras polyinsatures
Johari et al. Evaluation of antioxidant activity of essential oils of some Indian medicinal plants by DPPH, FRAP and ABTS assay
JPH1175770A (ja) 過酸化脂質生成抑制剤、その製造法および利用
LC Albuquerque et al. Trends in annatto agroindustry: Bixin processing technologies and market
Okada et al. A study on fatty acids in seeds of Euterpe oleracea Mart seeds
PL187310B1 (pl) Naturalny preparat przeciwutleniający
Thao et al. Effect of extraction solvents on quality of Vietnamese tea (Camellia sinensis O. Kuntze) seed oil
Franek et al. The chemical composition, nutritional value, and possibility of use Cannabis sativa L. seeds in animal nutrition
WO2009126976A1 (fr) Compositions antioxydantes
Ramadan Cold pressed cumin (Cuminum cyminum) oil

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210908

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)